1. Apple launches virtual health studies with thousands of customers —FDA panel says no to Lilly/Boehringer’s Jardiance for type 1 diabetes — ICER creates new gene therapy pricing framework — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Pacira Contract

Discussion in 'Innovex' started by Anonymous, Dec 5, 2011 at 11:12 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    what you have here ,,,,is a failuuuuure to communicate



    From the prison guard to Paul Newman
     
  2. Anonymous

    Anonymous Guest


    there is no failure to communicate....there is a culture of lying. lied when they hired the salesforce, lied about the product availability, lied about the 1st quarter bonus, lied about the J code, lied about compensation again and again ---and just listen to those investor calls.
     
  3. Anonymous

    Anonymous Guest

    Reduce expenses/debt, improve the books to make the company attractive to a buyer, sell at a good price, Stack cashes in his stock options, and walk. This is not a long term company. We all knew this going in.
     
  4. Anonymous

    Anonymous Guest

    IF they don't destroy the product and the company ..........before they can sell it
     
  5. Anonymous

    Anonymous Guest

    Very bad comp plan....people will start moving on just when you need the best.

    What are you thinking PaulC. You have bad performers reaching the 40 dol threshold early and screwing your top people...not good,!
     
  6. Anonymous

    Anonymous Guest

    "bad performers"? get over yourself. go do some work..its called growing your business
     
  7. Anonymous

    Anonymous Guest

    This is a top performer Asswipe!
     
  8. Anonymous

    Anonymous Guest

    its a company full of unqualified hacks who knew or sucked up to the right person--stack. they are an FDA and SEC sitting duck --if anyone ever takes a good look at the widespread promotion for tap block and other uses for which there is no data or indication it could be ugly --or leaking early data results ....
     
  9. Anonymous

    Anonymous Guest

    people "will start moving on"????? REALLY? Almost my entire district is GONE!! I think we are all looking, especially based on how they've treated us since being brought over to Pacira.
     
  10. Anonymous

    Anonymous Guest

    Pretty simple, they only need us to get surgeons to use it. Once it becomes habit, you become expendable.
     
  11. Anonymous

    Anonymous Guest

    No matter what anyone at corporate says, this one product company could be sold at any point. DW a national sales manager? He's a pharmacist with no sales experience. Have to question who made that decision. There will be a mass exodus from this lack-of-management company which devalues its' sales force.
     
  12. Anonymous

    Anonymous Guest

    Pacira is for sale to the bidder with the right price-it is not a viable company with one product that costs so much to manufacture, ship and sell; exparel is competing in a market with many generic (i.e cost effective) and effective alternatives, it is a niche product that primarily belongs in the ambulatory setting or short stay surgery and can only truly expand in a significant way when and IF it gets the nerve block indication. Even that indication is no guarantee-you cannot turn exparel off. it has risks. you can remove a pain ball if there are problems, you can turn off the epidural. once exparel is injected it is there for 96 hours..........that is not necessarily something everybody views as a good thing.
     
  13. Anonymous

    Anonymous Guest

    DW national sales manager. Enough said.
     
  14. Anonymous

    Anonymous Guest

    and homer
     
  15. Anonymous

    Anonymous Guest

    Its like the people here just sit there and spank the monkey,,,im just sayen,,

    everyone is all over the place and spinning wheels,,,lets get it together folks

    drop your thing and start doing the things that will move this drug...
     
  16. Anonymous

    Anonymous Guest

    Name Number of Shares of Common Stock Underlying Option
    David Stack 350,000
    James Scibetta 150,000
    Taunia Markvicka 150,000
    John Pratt 150,000
    Gary Patou, M.D. 40,000
    Lauren Riker 30,000
     
  17. Anonymous

    Anonymous Guest

    Think the stock is way overvalued. Wonder how that happens when other hire performing companies have to try so much harder to keep prices up.
     
  18. Anonymous

    Anonymous Guest

    Not to mention all the off-label usage of this stuff by orthopods-----it will be fun to sit back and watch all the lawsuits roll in when Exp gets into a few joints.........
     
  19. Anonymous

    Anonymous Guest

    off label is much of the use...........and they are promoting nerve block like crazy.
     
  20. Anonymous

    Anonymous Guest

    Pacira Pharmaceuticals, Inc.
    Compensation for 2011
    Salary $409,046
    Bonus $206,000
    All other compensation $1,504
    Total Compensation $616,550
    Options Exercised for 2011
    Number of securities underlying options exercisable 151,095
    Number of securities underlying options unexercisable 34,865
    Stock Ownership for 2011
    Number of shares owned 20,600